Table 6.
Three-Year Incidence of Neurocognitive Diagnoses Among Patients With Any HF (ICD-10-CM: I50) Receiving Sacubitril/Valsartan vs Propensity Score Matched Patients Receiving ACEIs or ARBs
| Sacubitril/Valsartan (n = 13,323)a |
ACEI/ARB (n = 13,323)a |
HR (95% CI) | P Value | |||
|---|---|---|---|---|---|---|
| Events | 3-y K-M Estimate | Events | 3-y K-M Estimate | |||
| Primary endpoint | 985 | 10.5% | 1,296 | 13.5% | 0.76 (0.70-0.82) | <0.001 |
| Cognitive decline | 865 | 9.1% | 1,149 | 11.8% | 0.76 (0.69-0.82) | <0.001 |
| Dementia | 333 | 3.4% | 446 | 4.4% | 0.76 (0.66-0.88) | <0.001 |
| Alzheimer’s disease | 73 | 0.7% | 122 | 1.2% | 0.61 (0.46-0.82) | 0.001 |
ACEI = angiotensin-converting enzyme inhibitor; ARB = angiotensin II receptor blocker; HF = heart failure; ICD-10-CM = International Classification of Diseases-10th Revision-Clinical Modification; K-M = Kaplan-Meier.
Patients with prevalent diagnoses of interest at baseline were excluded from calculation of incidence for each analysis. Outcomes were defined using the following ICD-10-CM codes: dementia (vascular dementia [F01], dementia in other diseases [F02], and unspecified dementia [F03]), Alzheimer’s disease [G30], cognitive decline (other symptoms and signs involving cognitive functions and awareness, R41.8]). The primary endpoint was defined as the composite (first occurrence) of any of these diagnoses.